Evolution of drug-resistant ovarian-cancer clones tracked in patients

After an initial treatment response, most ovarian cancers recur because of drug-resistant cell populations. Blood-based tracking, used to monitor clonal evolution in 18 patients, shows that drug-resistant clones are already present at diagnosis, expand during therapy and contain distinctive genomic alterations that have potential therapeutic relevance.